VA Dual Sequential Therapy
NCT06929962 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600
Last updated 2025-05-20
Summary
Sequential therapy for Hp was first introduced by Zullo et al. in 2000 and consists of two phases: the first phase involves proton pump inhibitors with one antibiotic, and the second phase involves proton pump inhibitors with two antibiotics. Based on this, the investigators propose a modified sequential therapy, where the first phase uses vonoprazan combined with amoxicillin, and the second phase increases the amoxicillin dosage, forming a high-dose amoxicillin regimen. This new treatment strategy combines the staged nature of sequential therapy with the advantages of high-dose dual therapy, gradually increasing the drug dosage to help patients adapt and reduce side effects (such as nausea, vomiting, and diarrhea), thereby improving patient tolerance.
The primary aim of this study is to compare the vonoprazan combined with high-dose amoxicillin sequential therapy with standard dual therapy (14-day regimen) in terms of Hp eradication rates, efficacy, side effect incidence, and patient compliance, to evaluate its improved effectiveness. Additionally, the study will explore the impact of a shortened treatment duration on the modified dual sequential therapy's efficacy for Hp infection.
Eligible participants in this study will be randomly assigned to one of the following three treatment groups based on a pre-generated randomization sequence:
Control Group: Vonoprazan combined with high-dose amoxicillin dual therapy for 14 days (VADT-14): Vonoprazan 20mg twice daily + Amoxicillin 1g three times daily.
Experimental Group 1: Vonoprazan combined with amoxicillin dual sequential therapy for 14 days (VAST-14):
Days 1 to 7: Vonoprazan 20mg twice daily + Amoxicillin 1g twice daily. Days 8 to 14: Vonoprazan 20mg twice daily + Amoxicillin 1g three times daily.
Experimental Group 2: Vonoprazan combined with amoxicillin dual sequential therapy for 10 days (VAST-10):
Days 1 to 5: Vonoprazan 20mg twice daily + Amoxicillin 1g twice daily. Days 6 to 10: Vonoprazan 20mg twice daily + Amoxicillin 1g three times daily.
Conditions
- Helicobacter Pylori Infection
Interventions
- DRUG
-
Vonoprazan and Amoxicillin for the first 7 days
20mg Vonoprazan twice times daily and 1g Amoxicillin twice times daily for 7 days
- DRUG
-
Vonoprazan and Amoxicillin for the first 5 days
20mg Vonoprazan twice times daily and 1g Amoxicillin twice times daily for 5 days
- DRUG
-
Vonoprazan and Amoxicillin for the second 7 days
20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 7 days
- DRUG
-
Vonoprazan and Amoxicillin for the second 5 days
20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 5 days
- DRUG
-
Vonoprazan and Amoxicillin for 14 days
20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 14 days
Sponsors & Collaborators
-
The First Affiliated Hospital with Nanjing Medical University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-24
- Primary Completion
- 2026-12-01
- Completion
- 2026-12-31
Countries
- China
Study Locations
More Related Trials
-
Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection
NCT07275827 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis
NCT03908619 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of Vonoprazan in Eradication of Resistant Strain of Helicobacter Pylori
NCT06414707 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients
NCT04728516 ·Status: RECRUITING ·Phase: PHASE4
-
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy
NCT02296021 ·Status: COMPLETED ·Phase: PHASE4
-
Vonoprazan for Helicobacter Pylori Eradication in Adolescents
NCT06162949 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
NCT04167670 ·Status: COMPLETED ·Phase: PHASE3
-
High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication
NCT01888237 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection
NCT07040839 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication
NCT06101420 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets
NCT06337604 ·Status: COMPLETED ·Phase: PHASE1
-
AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers
NCT00325715 ·Status: COMPLETED ·Phase: PHASE1
-
Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication
NCT05014334 ·Status: COMPLETED ·Phase: PHASE4
-
Gastric pH in Critically Ill Patients
NCT00590928 ·Status: COMPLETED ·Phase: PHASE4
-
Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding
NCT06783257 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori
NCT02767479 ·Status: COMPLETED ·Phase: PHASE3
-
PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers
NCT05582174 ·Status: RECRUITING ·Phase: PHASE4
-
Tegoprazan- Versus PPI-based H. Pylori Eradication
NCT06682533 ·Status: RECRUITING
-
Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
NCT03362281 ·Status: COMPLETED ·Phase: PHASE3
-
Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer
NCT00471029 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety Study of Esomeprazole vs Omeprazole to Treat Acute Non-Variceal Upper Gastrointestinal Bleeding
NCT00402259 ·Status: COMPLETED ·Phase: PHASE3
-
Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)
NCT05647278 ·Status: COMPLETED ·Phase: PHASE4
-
Helicobacter Eradication Relief of Dyspeptic Symptoms
NCT00404534 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Low Against High Regimen of Proton Pump Inhibitors for Treatment of Acute Peptic Ulcer Bleeding
NCT02724150 ·Status: WITHDRAWN ·Phase: PHASE4
-
Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
NCT06217393 ·Status: COMPLETED ·Phase: PHASE3